Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity

Patients treated with anticancer chemotherapy exhibit variation, both in terms of tumor response and the incidence and severity of adverse effects. The etiology of this variation is multifactorial with genetic factors likely contributing to a significant extent. Pharmacogenetic and genomic studies c...

Full description

Saved in:
Bibliographic Details
Published inPharmacogenomics Vol. 8; no. 9; pp. 1159 - 1168
Main Authors Hartford, Christine M, Dolan, M Eileen
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.09.2007
Subjects
Antineoplastic Agents - pharmacology
Antineoplastic Agents - toxicity
Cell Survival - drug effects
chemotherapy
cytotoxicity
Genetic Variation
Genome, Human
Humans
lymphoblastoid cell lines
Neoplasms - drug therapy
Neoplasms - genetics
Neoplasms - pathology
pharmacogenomics
whole-genome
Online AccessGet full text

Cover

More Information
Summary:Patients treated with anticancer chemotherapy exhibit variation, both in terms of tumor response and the incidence and severity of adverse effects. The etiology of this variation is multifactorial with genetic factors likely contributing to a significant extent. Pharmacogenetic and genomic studies can be used to identify the genetic variants that contribute to interindividual variation in susceptibility to chemotherapy-induced cytotoxicity. This review will describe candidate and whole-genome approaches, describe the advantages and disadvantages of each, and illustrate how they can be used to obtain clinically relevant information. Specific emphasis is given to recent advances emerging from the International HapMap Project and to the development of genetic signatures, as opposed to expression signatures, to explain drug sensitivity and resistance.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1462-2416
1744-8042
DOI:10.2217/14622416.8.9.1159